MHRAapproval72% confidence
Clinical trials for medicines: modifying a clinical trial approval
Source: MHRA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (immunology) as AbbVie.
Regulatory Analysis
Guidance on the various types of modifications that can be made to a clinical trial approval.
Supporting Context
- Therapeutic area
- Dermatology · Atopic Dermatitis
- Sub-indication
- Immunology
Related signal: AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders